Significant Biotech Investment Rounds in July 2025
Headline: MapLight Therapeutics Secures Largest Private Biotech Funding Round in July 2025
In the dynamic world of biotech investments, July 2025 saw a significant event as MapLight Therapeutics raised an impressive $372.5 million in a Series D financing round. This funding will propel the company's lead program for schizophrenia and Alzheimer’s disease psychosis through ongoing Phase 2 trials and explore other indications.
This round was notably the largest private biotech funding event in July 2025, substantially exceeding other rounds that month. Other notable private biotech fundraisings included:
- Artbio, a radiopharmaceutical company, raised $132 million in a Series B round to support the development of its lead asset AB001 for metastatic castration-resistant prostate cancer, including phase 2 trials and manufacturing scale-up.
- Avalyn Pharma completed a $100 million Series D round to fund clinical milestones for its pulmonary fibrosis programs, including advanced development of inhaled formulations of pirfenidone and nintedanib.
- AdvanCell, an Australian radiopharma company, raised $112 million in a Series C round (closing just before August) for its prostate cancer-targeted therapy development.
While MapLight Therapeutics' funding round was the largest, it was not the only significant event in the biotech industry last month. The public biotech fundraising exceeded private biotech fundraising for the second month in a row, with a total of $1.898 billion raised. Inflammatory diseases had the highest public fundraising, with Abivax's $747.5 million public offering.
Interestingly, despite oncology companies having the most funding rounds in July 2025, the therapeutic subsector of neurological conditions brought in the most money, despite only attracting two rounds. This trend was evident in Everest Medicines' $200 million share placement, which will be used to advance its global research and development of pipeline products, with a focus on 50% of the net proceeds dedicated to the treatment of metastatic castration-resistant prostate cancer.
Meanwhile, Soleno Therapeutics raised $200 million in a public offering, with the net proceeds to be used for the commercialization of VYKATTM XR for Prader-Willi syndrome. Abivax, on the other hand, aims to reach 12 months of expected cash runway following the planned NDA submission for ulcerative colitis, with the proceeds from its public offering financing its operations into Q4 2027.
The proceeds from these fundraisings will support key clinical milestones across various pipeline programs, including Avalyn's pipeline programs in pulmonary fibrosis, Artbio's development of AB001, and Everest Medicines' commercialization efforts.
In July 2025, North America had the highest total funding raised from private biotech investments, with companies headquartered in the region raising $768 million from seven rounds. Despite private biotech fundraising lagging behind its normal levels in July 2025, it is clear that the biotech industry continues to thrive, with promising developments and significant investments in various therapeutic areas.
[1] Source: BioPharma Dive [2] Source: Fierce Biotech
- Despite oncology companies having the most funding rounds in July 2025, the therapeutic subsector of neurological conditions brought in the most money, with Everest Medicines securing a $200 million share placement for its global research and development of pipeline products, focusing on treatment of metastatic castration-resistant prostate cancer.
- In the health-and-wellness sector, Soleno Therapeutics raised $200 million in a public offering, with the net proceeds to be used for the commercialization of VYKATTM XR for Prader-Willi syndrome.
- While MapLight Therapeutics' funding round was the largest in the biotech industry last month, Abivax's $747.5 million public offering was the highest public biotech fundraising for inflammatory diseases.
- In July 2025, investments in the biotech industry continued to demonstrate the sector's promise, with finance pouring into various therapeutic areas, including neurological disorders, medical-conditions, and health-and-wellness, as companies like Artbio, Avalyn Pharma, AdvanCell, and others carried out their research and development projects.
